Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

34.62
Delayed Data
As of Oct 20
 -0.09 / -0.26%
Today’s Change
25.55
Today|||52-Week Range
35.60
+26.72%
Year-to-Date
Celgene Down on Discontinued Crohn's Disease Drug Study
Oct 20 / Zacks.com - Paid Partner Content
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
Oct 13 / Zacks.com - Paid Partner Content
Cancer Treatment Update: Second Gene Therapy Receives Approval
Oct 20 / Zacks.com - Paid Partner Content
Valeant Reports Positive Results on Psoriasis Drug Siliq
Oct 13 / Zacks.com - Paid Partner Content
Roanoke Asset Management Corp Buys DowDuPont Inc, Visa Inc, Sells E.I. ...
Oct 20 / GuruFocus News - Paid Partner Content
Cancer Space Update: Lung & Breast Cancer Studies in Focus
Oct 13 / Zacks.com - Paid Partner Content
AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
Oct 19 / Zacks.com - Paid Partner Content
Lilly's Verzenio Gets Priority Review in First-Line Setting
Oct 13 / Zacks.com - Paid Partner Content
Bristol-Myers Gets Priority Review for Opdivo Label Expansion
Oct 17 / Zacks.com - Paid Partner Content
Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca
Oct 10 / Zacks.com - Paid Partner Content
Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
Oct 16 / Zacks.com - Paid Partner Content
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
Oct 09 / Zacks.com - Paid Partner Content